Nov 20, 2025 · Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We …

Check out the drug pipeline for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing synthetic lethal therapies.

Learn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.

Learn about scientifc discovery platorm at Repare Therapeutics, a clinical-stage precision oncology company developing novel, synthetic lethal medicines.

Corporate Profile for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.

Apr 25, 2025 · Press releases for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines.

Repare is developing a small molecule inhibitor of polymerase theta, or Polθ, a SL target associated with BRCA mutations and other genomic alterations.

Jul 15, 2025 · Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best …

May 1, 2025 · Repare has utilized its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic …